Literature DB >> 17334509

Platelet activation via PAR4 is involved in the initiation of thrombin generation and in clot elasticity development.

Karin Vretenbrant1, Sofia Ramström, Maria Bjerke, Tomas L Lindahl.   

Abstract

Thrombin is a pivotal enzyme formed in the coagulation cascade and an important and potent platelet activator. The two protease-activated thrombin receptors on human platelets are denoted PAR1 and PAR4. The physiological relevance of PAR4 is still unclear, as both aggregation and secretion can be accomplished by PAR1 activation alone. In the present study we have investigated the role of PARs in platelet activation, blood coagulation, clot elasticity and fibrinolysis. Flow cytometry, free oscillation rheometry and thrombin generation measurements were used to analyze blood or platelet-rich plasma from healthy individuals. Maximum PAR1 activation with the peptide SFLLRN gave fewer fibrinogen-binding platelets with lower mean fluorescent intensity than maximum PAR4 activation with AYPGKF. Inhibition of any of the receptors prolonged clotting times. However, PAR1 is more important for fibrinolysis; inhibition of this receptor prolonged all the steps in the fibrinolytic process. Clot elasticity decreased significantly when the PAR4 receptor was inhibited. In the thrombin generation measurements, PAR4 inhibition delayed the thrombin generation start and peak, but did not affect the total amount of thrombin generated. PAR1 inhibition had no significant impact on thrombin generation. We found that PAR4 is most likely activated by low concentrations of thrombin during the initial phase of thrombin generation and is of importance to the clotting time. Furthermore, we suggest that the PAR4 receptor may have a physiological role in the stabilisation of the coagulum.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17334509

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  8 in total

1.  Activation of protease-activated receptors 3 and 4 accelerates tissue factor-induced thrombin generation on the surface of vascular smooth muscle cells.

Authors:  Param Vidwan; Alokkumar Pathak; Samar Sheth; Jianhua Huang; Dougald M Monroe; George A Stouffer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-10-07       Impact factor: 8.311

2.  Contributions of Protease-Activated Receptors PAR1 and PAR4 to Thrombin-Induced GPIIbIIIa Activation in Human Platelets.

Authors:  Matthew T Duvernay; Kayla J Temple; Jae G Maeng; Anna L Blobaum; Shaun R Stauffer; Craig W Lindsley; Heidi E Hamm
Journal:  Mol Pharmacol       Date:  2016-10-26       Impact factor: 4.436

3.  Protease-activated receptor (PAR) 1 and PAR4 differentially regulate factor V expression from human platelets.

Authors:  Matthew Duvernay; Summer Young; David Gailani; Jonathan Schoenecker; Heidi E Hamm; Heidi Hamm
Journal:  Mol Pharmacol       Date:  2013-01-10       Impact factor: 4.436

4.  PAR4 activation involves extracellular loop 3 and transmembrane residue Thr153.

Authors:  Xu Han; Lukas Hofmann; Maria de la Fuente; Nathan Alexander; Krzysztof Palczewski; Marvin T Nieman
Journal:  Blood       Date:  2020-11-05       Impact factor: 25.476

5.  Platelet aggregation but not activation and degranulation during the acute post-ischemic reperfusion phase in livers with no underlying disease.

Authors:  Rowan F van Golen; Katarzyna M Stevens; Pina Colarusso; Hartmut Jaeschke; Michal Heger
Journal:  J Clin Transl Res       Date:  2015-09-13

6.  Protease-activated receptor-mediated platelet aggregation in acute coronary syndrome patients on potent P2Y12 inhibitors.

Authors:  Patricia P Wadowski; Joseph Pultar; Constantin Weikert; Beate Eichelberger; Benjamin Panzer; Kurt Huber; Irene M Lang; Renate Koppensteiner; Simon Panzer; Thomas Gremmel
Journal:  Res Pract Thromb Haemost       Date:  2019-05-22

Review 7.  Pulmonary Artery Thrombosis: A Diagnosis That Strives for Its Independence.

Authors:  Olga Porembskaya; Yana Toropova; Vladimir Tomson; Kirill Lobastov; Leonid Laberko; Viacheslav Kravchuk; Sergey Saiganov; Alexander Brill
Journal:  Int J Mol Sci       Date:  2020-07-18       Impact factor: 5.923

8.  Varying effects of tyrosine kinase inhibitors on platelet function-A need for individualized CML treatment to minimize the risk for hemostatic and thrombotic complications?

Authors:  Suryyani Deb; Niklas Boknäs; Clara Sjöström; Anjana Tharmakulanathan; Kourosh Lotfi; Sofia Ramström
Journal:  Cancer Med       Date:  2019-11-12       Impact factor: 4.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.